EUVIMEDEUVIMED entdecken
Crossref

Emicizumab Therapy for Hemophilia Persons; Pilot study; non-Intentional Delay of Maintenance Doses

Abdulaziz Wannas Abd *

Clinical Research and Clinical Reports · 22.02.2024 · 04 (01) · 01-03

DOI: 10.31579/2835-8325/061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research and Clinical Reports, online erschienen am 22.02.2024. Verfasst von Abdulaziz Wannas Abd *.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emicizumab represent the first non- factor replacement therapy, which is new treatment not require for intravenous access and used for patient with hemophilia A and the information’s from 3 phases demonstrated that emicizumab is safe and effective and improved the life style for person with hemophilia A. This drug represents the first non- factor replacement therapy, which is new treatment not require for intravenous access and used for patient with hemophilia A and the information’s from 3 phases demonstrated that emicizumab is safe and effective and improved the life style for person with hemophilia A. The objective of this papers to assess and evaluate bleeding episode for patients with delayed maintenance monthly doses of emicizumab. This study for small group Iraqi patients with severe hemophilia A with and without inhibitors exposed for non-intentional delayed for maintenance doses of emicizumab for seven months. The questionnaire included full general information’s about the age, weight, inhibitor status and other clinical details about general condition before and after initiation of emicizumab therapy. All patients age enrolled in this study were above 20 years old with a median age of at initiation of therapy and their weight more than 50 kilograms and most of them are hemophilia with inhibitor’s changed from factor VII therapy to emicizumab. Most of them exposed to different period maintenance treatment delayed for more than two weeks without any bleeding episodes. In conclusions this study shows delayed monthly maintenance dose of emicizumab dose without bleeding episodes. But because of small groups of patients were studied, so this cannot be regarded a standard treatment for all the patients. I recommend to use more data and large patients’ number with same period or emicizumab maintenance dose given every six weeks instead of four weeks.

Zitieren

APA

*, A. W. A. (2024). Emicizumab Therapy for Hemophilia Persons; Pilot study; non-Intentional Delay of Maintenance Doses. Clinical Research and Clinical Reports, 04(01), 01-03. https://doi.org/10.31579/2835-8325/061

Vancouver

* AWA. Emicizumab Therapy for Hemophilia Persons; Pilot study; non-Intentional Delay of Maintenance Doses. Clinical Research and Clinical Reports. 2024;04(01):01-03. doi:10.31579/2835-8325/061

BibTeX
@article{2024,
  author = {*, Abdulaziz Wannas Abd},
  title = {Emicizumab Therapy for Hemophilia Persons; Pilot study; non-Intentional Delay of Maintenance Doses},
  journal = {Clinical Research and Clinical Reports},
  year = {2024},
  volume = {04},
  number = {01},
  pages = {01--03},
  doi = {10.31579/2835-8325/061}
}
Kostenlos starten →